Blog

Bellicum Offers A Promising Stock At Throwaway Prices – Seeking Alpha


Seeking Alpha

Bellicum Offers A Promising Stock At Throwaway Prices
Seeking Alpha
The company also has strong potential to build a niche for itself in the cutting edge CAR-T segment. Bellicum recently reported important updates for its lead drug candidates BPX-501, which is an adjunct Tcell therapy for allogeneic hematopoietic stem

2017-08-17 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.